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Background: Carrier screening is generally performed with the aim of identifying healthy couples at risk of having
a child affected with a monogenic disorder to provide them with reproductive options. Expanded carrier screening
(ECS), which provides the opportunity for multiple conditions to be screened in one test, offers a more cost-effective
and comprehensive option than screening for single disorders. However, implementation of ECS at a population level
would have implications for genetic counseling practice.
Methods: We conducted semi-structured interviews with sixteen European clinical and molecular geneticists with
expertise in carrier screening to explore their views on the implementation of ECS in the clinical setting.
Results: Using inductive content analysis, we identified content categories relevant to the pre- and post-test settings.
Participants believed ECS would ideally be targeted at couples before pregnancy. There was some disagreement
regarding the acceptability of performing ECS in individuals, with several participants actively opposing individual-
based screening. In addition, participants discussed the importance of ensuring informed and voluntary participation
in ECS, recommending measures to minimize external pressure on prospective parents to undergo testing. A need for
adequate counseling to foster informed, autonomous reproductive decision-making and provide support for couples
found to be at risk was emphasized.
Conclusions: Practical challenges in optimizing pre-test education and post-test counseling should not be
underestimated and they should be carefully addressed before implementing ECS in the clinical setting.
Keywords: Expanded carrier screening, Pre-test counseling, Post-test counseling, InterviewsBackground
Carrier screening aims to identify couples at risk of
having a child affected with a monogenic (autosomal or
X-lined) recessive disorder. In autosomal recessive disor-
ders, both members of an at-risk couple are usually un-
affected carriers of a single faulty copy of the gene
associated with the same disorder, while in X-linked dis-
orders, only the female partner is a carrier. In both
cases, such couples (henceforth referred to as carrier
couples) run a 25% chance of conceiving an affected* Correspondence: sandra.janssens@ugent.be
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couples have no family history of the disorder, they are
often unaware of their reproductive risks [1]. Thus, iden-
tification of carrier couples via carrier screening has the
potential to enhance their reproductive autonomy,
allowing them to make informed decisions. Carrier cou-
ples have the option to utilize preimplantation genetic
diagnosis or prenatal diagnosis to avoid having an af-
fected child [2], or can conceive naturally, prepare for
the birth of a potentially affected child and, in some
cases, initiate treatment in the newborn period [3].
Traditionally, due to technical and economic con-
straints, carrier screening had been performed for single
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of pathogenic mutations. Expanded carrier screening
(ECS) represents an evolution from single- to multi-
disease screening panels, driven by continuous advances
in genomic technologies and improved understanding of
the genetics of monogenic disorders [4]. Screening for
upwards of a hundred recessive disorders in a single test,
ECS has the potential to detect more carrier couples at
risk of having an affected child in the general population.
With the decrease in costs and improvements in carrier
detection rates, ECS is rapidly becoming an integral part
of reproductive healthcare [5, 6]. In particular, in the US,
more than 200,000 ECS tests are performed in prospective
parents annually, primarily through commercial genetic
testing providers [7]. In Europe, adoption of ECS has been
relatively slow, with testing being largely limited to high-
risk ethnic populations and patients undergoing artificial
reproduction [8, 9]. However, recent studies have shown
that members of the general public in Europe are inter-
ested in ECS [10, 11] and the demand for and uptake of
ECS tests is likely to increase in many European countries
in the near future.
As with all new medical technologies, adoption of ECS
comes with its own set of practical and ethical chal-
lenges. In particular, issues relating to devising optimal
screening strategies, provision of genetic counseling, and
developing the best clinical practices will need to be ad-
dressed in the near future. In the US, several studies
have investigated geneticists and other healthcare pro-
viders’ opinions on ECS [5, 12–14] and some profes-
sional organizations have developed recommendations
concerning its use [15, 16]. However, in Europe, discus-
sion on ECS has only recently gained traction, with the
first professional document addressing ECS published in
2016 [17]. In this paper, we report European geneticists’
attitudes towards ECS, focusing on their concrete sug-
gestions and recommendations for the use of ECS in the
clinical setting.
Methods
This study utilized semi-structured interviews to explore
the views of European geneticists on various aspects of
ECS. The interview guide used in the study consisted of
open-ended questions addressing various issues related
to ECS, with a particular emphasis on the challenges to
implementing ECS into clinical practice. Our goal was to
perform expert interviews with geneticists possessing ex-
tensive research, clinical and/or counselling experience
in carrier screening [18]. To this end, we employed pur-
posive sampling to identify potential participants, taking
into consideration their authorship of relevant academic
publications, conference abstracts and policy papers. As
the recruitment continued concurrently with the inter-
views, we additionally asked our participants to nominatetheir colleagues who they believed were qualified to discuss
ECS-related issues (snowball sampling).
Potential participants were approached by email and
those who agreed to participate were interviewed during
the period April to August 2014, either in person or via
Skype. Informed consent was obtained from all participants
included in the study. The questions addressed in this
paper were part of a study exploring ECS more broadly, in-
cluding recommendations for the composition of ECS
panels and the desirability of population-wide ECS [19, 20].
Inductive content analysis was used to identify common
content categories from the interviews [21–23]. The data
resulting from the interviews were initially coded into
broad categories using the qualitative data management
software QSR Nvivo. This initial phase of coding was per-
formed by DC for all the interview transcripts and cross-
validated by DV. In the subsequent phase, sections of the
data within the broad categories were compared by all
members of the research team and specific content cat-
egories were proposed in group discussions. Decisions on
the specific categories were reached by consensus.
The study was approved by the institutional ethics
committee of the University Hospital Ghent.
Results
We interviewed sixteen geneticists based in eight European
countries (member states of the European Economic Area).
This group comprised thirteen clinical geneticists (CG),
two molecular geneticists (MG), and one geneticist with
professional experience in both molecular and clinical
genetics (CMG). Most participants (12/16) had more than
20 years of professional clinical or diagnostic experience at
the time of the study and all held an academic affiliation.
In total, participants discussed four main concepts relat-
ing to the provision of ECS: (1) strategies for offering
screening, (2) ensuring informed decision-making, (3) com-
munication of individual carrier status, and (4) counseling
of carrier couples. We have organized these into two broad
categories, depending on whether they relate to pre- or
post-test setting (Table 1). These categories, along with il-
lustrative quotes, are described below.
Category 1. Pre-test considerations
Subcategory 1.1. Strategies for providing population-wide
ECS
Participants discussed optimal strategies for offering ECS
to prospective parents, focusing on two aspects: the timing
of screening and whether screening individuals was appro-
priate, compared to only offering screening to couples.
Timing of screening All participants agreed that ECS
should ideally be offered to couples in the preconception
period, when reproductive partners have already made
their plans about having children.
Table 1 An overview of content categories discussed during
the interviews
Category 1. Pre-test considerations
Subcategory 1.1 Strategies for providing population-wide ECS
• Timing of screening
• Issues with screening of individuals
Subcategory 1.2 Ensuring informed decision-making
• Providing neutral information about ECS
• Nondirective offers of testing
• Informed decisions about disorders to be screened
Category 2. Post-test considerations
Subcategory 2.1 Communication of individual carrier status
Subcategory 2.2 Counseling of carrier couples
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which are planning, or would be planning to have a
baby. Not being pregnant yet, and not being too far
away from the pregnancy.” (Interview 1, CG)
Nevertheless, most participants acknowledged the im-
portance of also allowing people access to ECS during
pregnancy. Several participants noted that the lack of
awareness of carrier screening among non-pregnant
couples, and the possibility of unplanned pregnancies,
suggests couples may only find out about ECS in the
prenatal period.
“When you have a pregnancy it is too late. But
unfortunately there is going to be a lot of cases like that,
because this is what you see now.” (Interview 10, CG)
Issues with screening of individuals All participants
agreed that screening both partners was optimal, and
supported a couple-based approach to carrier screening.
Participants also discussed the possibility of screening
individual prospective parents seeking carrier screening
without a reproductive partner. In general, participants
viewed screening of individuals in this situation as more
problematic, articulating several reasons against this ap-
proach. However, there was no agreement regarding re-
jection of individual-based screening: while some argued
that ECS should be provided exclusively to couples, sev-
eral participants believed that ECS could also be offered
to individuals. Most participants who were against
screening of individuals, drew attention to the lack of
clinical utility in this approach.
“[The] goal of the preconception screening is to find
carrier couples. It’s not interesting to find individual
carriers because this doesn’t have any consequences.
Any medical consequences.” (Interview 5, CG)
For another participant, screening of individuals was
morally problematic due to the possibility that thisapproach could motivate some prospective parents to
select their future reproductive partner based on genetic
compatibility.
“No, I’m not in favor of that [screening individuals
while they are single]. I find it a strange thing. [This
may lead to] a whole thing of matching people, you
know, all over the world.” (Interview 12, CG)
According to another participant, undergoing carrier
screening is a decision that has to be made by both
members of the couple and must be mutually agreed on.
“I do think that this is something that they have to do
together. Not just because for us it’s more informative
to have both partner[s]. But this is also a process that
must be done together as a couple. So we want a baby,
we are getting tested in order to know if we are
carriers … So it’s something we are doing together, not
just the woman goes and gets tested.” (Interview 7,
MG; emphases by the participant)
On the other hand, those participants who favored pro-
viding ECS to individuals emphasized the importance of
the carrier status information for family members.
“[T]here are family implications of these results. So it’s
hard to say it’s just something which is important as a
couple, because I mean, it can be important for the
family members as well.” (Interview 13, CG)
Another participant mentioned that there may be value
in performing individual-based carrier screening as it
reduces uncertainty in prospective parents who are
worried that they may be carriers based on their family
history. However, they also noted that screening of
individuals for autosomal recessive disorders does not
carry public health benefits and thus should only be per-
formed in the commercial setting.
“[You] have to offer it to individuals … [because] in
the real world, somebody who has a [relative] with
[a recessive disorder], is going to ask for it. So, if they
want to pay for it privately, go ahead and have [it].”
(Interview 9, CG)Subcategory 1.2 Ensuring informed decision-making
All participants discussed the importance of couples (or
individuals) making informed decisions about undergoing
ECS. To achieve this, participants identified three neces-
sary conditions: providing neutral information about ECS,
nondirective offers of testing, and informed decisions about
disorders to be screened.
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suggested that in order to facilitate access to screening
in the preconception period, efforts should be made to
inform the public about ECS. However, several partici-
pants were concerned that prospective parents may then
feel obliged to take the test.
“If you are going to offer it, there must be some public
campaign, saying that it’s there. But … if you are
making a very big campaign, then people would think
‘oh, I should do that, because otherwise I’m stupid and
it’s my own choice to have a baby with a handicap’.
And that’s not the message I want to bring across.”
(Interview 3, CG)
Some participants were worried that concerns over the
health of one’s future child could make prospective par-
ents susceptible to pressure from ECS providers, particu-
larly if it is offered by direct-to-consumer genetic testing
companies. According to some, these companies tend to
downplay the limitations of their products and overstate
the potential benefits of carrier screening, which “might
lead to unrealistic expectations” (Interview 16, CG). Con-
sequently, the majority of interviewees expressed their
strong disapproval of direct-to-consumer ECS products.
“When you look at the website of [name of a company]
for example, the text on [it] is just awful. It’s like: ‘who
doesn’t want to prevent the birth of a child with a
genetic disease?’ And ‘it’s your responsibility’. And it’s a
very coercive way of informing the people.” (Interview
2, CG)
Our participants argued that pre-test information pro-
vided to prospective parents should clearly emphasize
the limitations of ECS, including that ECS may identify
mutations with limited clinical significance but also fail
to identify some carriers.
“[E]ither you have to tell them: ‘I may find stuff that
I’ll not be able to explain to you’ or you have to tell
them: ‘I will only look at the known stuff [and] I’m
going to give you a … more informed answer, but this
is going to cover slightly less. So you’ll still have a
chance of having a child with a recessive disorder.”
(Interview 10, CG)
Nondirective offers of testing According to the partici-
pants, as many prospective parents in the general public
are likely to be unaware of the option of carrier screen-
ing, discussions about ECS would generally need to be
initiated by a healthcare provider. However, participants
cautioned that in order to allow prospective parents suf-
ficient time to weigh the advantages and disadvantagesof ECS and make an informed decision consistent with
their values, the actual offer of screening should not take
place immediately.
“I wouldn’t want … [testing] to be very closely linked in
time to the information-offering. Because if it forces people
to make choices quickly, then really what they need is
time and space to think about that.” (Interview 14, CG)
To ensure the offer of ECS is non-directive, several partic-
ipants suggested the main role of healthcare professionals
in the pre-test setting should be to explain the basics of
ECS to their patients and provide them with appropriate
educational resources to peruse in their own time.
“I think that you should explain, but very briefly, the
mode of transmission. You should explain that the
father, the mother, they are healthy but they are
carriers of the disease. … [For the rest,] you should
also have for some people some leaflets … [also,
you should tell them]: ‘you can go on this site,
and be careful about the other site’ … so when
they are at home, if they wish, they [can access]
it.” (Interview 15, CG)
In general, our participants supported the use of audio-
visual aids, such as leaflets, websites, and brochures, as
an alternative to detailed pre-test counseling. This was
recommended to avoid overloading prospective parents
with too much information during a consultation, re-
duce the workload for healthcare providers, and ensure
that all prospective parents receive the same, high-
quality information.
“I could well imagine a system where you have a
written leaflet and a very well, carefully constructed
YouTube 5-10 minute educational video clip that
people will be asked to access before testing. … It’s
[important] that people have leaflets, something
web-based educational, information-giving resource.”
(Interview 14, CG)
Informed decisions about disorders to be screened
Participants were concerned that due to the large
number of disorders that can be included on ECS
panels, prospective parents would have difficulty un-
derstanding the vast amount of information necessary
to make informed decisions regarding the disorders
for which they would want to be screened.
“[I]f you make a test where there are as well diseases
[leading to] babies dying in the first days of life and
diseases where they might become blind at the age of
twenty, that’s a totally different kind of decision for the
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make an informed choice.” (Interview 3, CG)
Following this logic, some argued that asking potential
parents to consent to screening for specific disorders
would be impractical, and that a more generic consent
would be preferable.
“You cannot ask a parent ‘do you want screening for
this disease and not for that disease?’ … You have to
give permission for all diseases and when the test is
positive for one of the diseases, then you get detailed
information.” (Interview 5, CG)
Despite the practical benefits of employing a generic
consent for ECS, some also pointed out that this ap-
proach fails to recognize differences among various dis-
orders, which they considered a weakness of this
approach. As a potential solution, a tiered approach to
consent was proposed, where diseases could be grouped
into categories based on common characteristics. This
would simplify the information for potential parents to
consider when making decisions about screening.
“You have to cluster [disorders] … [For example:]
There are diseases that are lethal in the first few years
of life and … this is for severe mental handicap…
[In this way,] people can make a decision: ‘I want to
know whether my baby has a risk of a lethal disease
or mental retardation.” (Interview 3, CG)
Category 2. Post-test considerations
When discussing the post-test setting, our participants
focused on issues such as communication of results,
genetic counseling, education and psychological support
of carrier couples.
Subcategory 2.1 Communication of individual carrier status
Participants who supported screening individuals believed
that it would be sufficient to communicate these results
either in written form or verbally by a non-genetics
healthcare provider. According to these participants, re-
ports should emphasize the meaning of the results.
“[It should be stated] in the report after that it’s
always a couple issue. So, you are a carrier, it’s not a
problem, everybody is a carrier of something … [s]hould
[your partner] be a carrier of the same … thing as you,
then there would be a risk.” (Interview 6, CMG)
Most participants agreed that in the case of couple-
based screening, both members of the couple should
have access to their individual test results. Interestingly,
some participants who opposed screening individualswere comfortable providing individual test results to
both partners in couple screening.
“I believe that [when] you give them the answer, then
you should tell them whatever [each of them] carries.
You’ll tell them: ‘look, you are carrying that, you’re
carrying that, there is no problem.’ … [M]y feeling
is that if you test the people and you find something,
at least they must have an option to know.”
(Interview 10, CG)
Another participant argued that individual carrier status
can be important in future relationships, expressing sup-
port for individual-based reporting of test results.
“[People may] change their partners. It’s a quite common
practice now. So … I think we have to [inform individual
carriers].” (Interview 8, CG)
While participants generally felt uneasy about not dis-
closing test results to couples, there was also some dis-
comfort in disclosing individual carrier results because,
as this participant stated, “carriership in one person of
the couple and not in the other is also unwanted infor-
mation, because that’s not important if you stay with the
same partner” (Interview 5, CG). In addition, one par-
ticipant displayed reluctance towards communicating in-
dividual results to the members of a screened couple,
stating that “technical problems of deciding in one per-
son if what you find is a pathogenic mutation … are too
[great]” (Interview 4, CG). In particular, they argued that
outside a small set of highly penetrant pathogenic
mutations, identifying persons as carriers of autosomal
recessive disorders based on their individual test results
would be misleading. According to this participant, since
the reproductive risk and the expected phenotype of the
affected child would depend on the joint genotypes of
both partners, individual test results should generally
not be communicated to couples undergoing ECS.
Finally, one participant was especially vocal in their
opposition to the disclosure of individual results, par-
ticularly in the context of a public health program which
aims to identify carrier couples.
“I think if you are trying to set up a public health
exercise and to identify couples at increased risk of a
child with a severe recessive condition, then you should
stick to that [goal] and not communicate things that
are not [relevant] to that. … ‘[You should] make it
very clear that even if they say ‘I want my individual
results’, that’s not something … that you feel is justified
in your public health exercise. … If your aim is
something else altogether, then you might say
differently.” (Interview 16, CG)
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All participants agreed that face-to-face genetic counsel-
ing is indicated for couples where screening identifies
that both members carry a pathogenic mutation associ-
ated with the same autosomal recessive disorder, or
where the female is a carrier of an X-linked disorder.
“[E]veryone who has a really high risk, carrier couples,
need genetic counseling. They are not well-off with only
a website or something.” (Interview 4, CG)
There was a consensus among participants that the goal
of post-test genetic counseling is to assist carrier couples
in making informed reproductive decisions. Participants
believed that counseling should include an explanation
of the genetic condition and discussion of their repro-
ductive options. However, the difficulty associated with
explaining the clinical aspects of a disorder, given the
couple may have no preexisting experience with the
condition, was noted.
“You are giving … the carrier couple information about
a condition of which they don’t have a first-hand
experience [with]. So, that imposes anxieties and
difficult decision processes on them. … [Because you
can’t] easily give an understanding of life with the
condition and its severity and impact on personal and
family life.” (Interview 14, CG)
To address this, several participants suggested involving
a medical professional with expertise in the disease.
They felt that post-test counseling and follow-up should
be provided neutrally and non-directively to allow pro-
spective parents to make uncoerced reproductive deci-
sions that are in line with their values.
“[I]f parents say, ‘ok’ – I have had already parents
even if they had a child with CF and say – ‘ok, I
take my chance, and I will have a child without
any prenatal diagnosis’, I respect completely, really.
It’s my opinion. I agree with all the choices of the
parents.” (Interview 15, CG)
Discussion
In this study, we have reported the views of European clin-
ical and molecular geneticists regarding the pre- and post-
test considerations required to implement population-wide
expanded carrier screening in an ethically sound way.
All the participants in our study believed that carrier
screening would ideally be offered to prospective parents
in the preconception period, which would maximize re-
productive autonomy for carrier couples by providing
both the greatest range of reproductive options and suf-
ficient time for decision-making. However, due to thepossibility of unplanned pregnancies, and limited aware-
ness of carrier screening among couples in the preconcep-
tion period, our participants believed carrier screening
should also be made accessible to pregnant couples, as
suggested by others [3, 17, 24–26].
We noted disagreement among participants regarding
whether it was appropriate to offer screening to individ-
uals, with some arguing that ECS should be performed
exclusively in couples. Although professional genetic or-
ganizations have endorsed both approaches [16, 17],
some of our participants identified important issues as-
sociated with performing carrier screening in individuals.
First, in autosomal recessive conditions, learning one’s in-
dividual carrier status is insufficient to estimate reproduct-
ive risks when a partner is not available for screening.
Should one’s (future) partner decline participation, ten-
sions may arise within the relationship and the individual
who had undergone ECS would be left with incomplete
information. Unavailability of the reproductive partner for
testing was also identified as an important barrier to indi-
vidual carrier screening in a recent focus group study with
women who had undergone a genomic carrier test [27].
Another potential advantage of couple-based screening is
the possibility to design panels to better meet the objec-
tives of the screening program. If the program aims to
identify only the couples at risk of having children affected
with a severe phenotype, a couple-based approach may
achieve this by selectively excluding carrier couples with
milder genotypes. For example, in mutations where more
severe phenotypes are associated with a compound het-
erozygous state while homozygosity typically leads to a
mild phenotype (such as R117H in cystic fibrosis or
N370S in Gaucher disease) [28–30], the screening pro-
gram may seek to identify couples at risk of having a com-
pound heterozygous child, while avoiding identification of
couples who may have a homozygous child. This would
only be possible if screening were to be performed exclu-
sively in couples. Furthermore, reporting of results would
also need to be couple-based, individual results would be
withheld, and, only couples at risk of having children with
a severe phenotype would be informed of their reproduct-
ive risks, whereas all others would receive negative results
[31]. However, this strategy is controversial as some re-
sults are not communicated [32, 33], the opportunity to
initiate cascade screening among family members of indi-
vidual carriers is foregone [25, 33], and individual carriers
cannot use their test results in subsequent relationships
[25]. Limiting carrier screening to couples would only be
reasonable in the case of autosomal recessive disorders,
since in X-linked recessive conditions, reproductive risks
can be accurately estimated even in the absence of the
male reproductive partner. Identifying some of these chal-
lenges, our participants generally agreed that both part-
ners should be entitled to receive their individual results
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ual- and couple-based approaches to screening have some
disadvantages, preferences between these two strategies
may vary across cultures and it may therefore be appropri-
ate to make the decision about whether to screen individ-
uals on a case-by-case basis, rather than through the
development of over-arching policies.
Participants also suggested prospective parents should
be provided with objective information to minimize the
possibility of coercion, preferably through appropriately
designed patient decision aids, such as videos, interactive
multimedia, and paper-based materials. This approach
would, as has been suggested by other authors, reduce
the burden on healthcare providers who may lack both
the time and the necessary expertise to educate their pa-
tients about ECS [34–36] and allow users to access and
process the information at their own pace [37]. Further-
more, it also acknowledges that prospective parents are
likely to require varying levels of information prior to
testing with some of them not desiring a detailed under-
standing of ECS [38]. Finally, receiving a carrier screening
offer from a medical professional, regardless of how non-
directive, may be misconstrued as an implicit recommen-
dation to take the test [25, 39], potentially influencing the
decision regarding screening. Due to the sensitive nature
of reproductive decisions, our participants highlighted the
necessity of ensuring that undergoing ECS is a fully in-
formed and voluntary decision that corresponds with the
couple’s personal values. To this end, our participants rec-
ommended that although in many cases a healthcare pro-
vider would initiate discussions about ECS, this should be
limited to a brief explanation of ECS and provision of edu-
cational materials. Additionally, several participants em-
phasized that requiring a repeat-visit for testing, instead
of performing ECS in the same-visit, would ensure that
future parents are making an active decision and are
motivated to undergo testing. This approach to carrier
screening has been described previously, with authors
arguing that requiring a repeat-visit would maximize
voluntary participation [40, 41]. However, the presence
of a barrier in accessing carrier screening, such as the
need for second visit, is likely to result in a lower up-
take of the test, as seen in studies of cystic fibrosis
screening programs [42]. It is important that the pro-
viders of carrier screening consider the potential trade-
off between informed and voluntary participation on
the one hand and uptake on the other.
Although utilizing educational materials has the po-
tential to increase informed decision-making, this goal
can only be accomplished if the information is presented
in an objective and neutral way. Our participants held
concerns that this may be more challenging if carrier
screening is offered by direct-to-consumer genetic test-
ing companies who employ audiovisual aids primarilyfor advertising purposes [35, 43]. Since many prospective
parents are highly motivated to do everything possible to
ensure the health of their offspring [27], they may be
susceptible to persuasion by advertisements which sug-
gest ECS as a guarantee to a healthy baby. Thus, it is im-
portant that pre-test educational tools are developed
with the aim of objectively informing prospective par-
ents about the benefits and disadvantages of ECS. To
this end, professional medical and genetic organizations,
rather than commercial providers of ECS, may be best-
placed to produce educational tools that convey objective
information, including the limitations of ECS, to prospect-
ive parents [16, 17].
In accord with discussions about the infeasibility of
disease-specific informed consent in the context of ECS
that have existed since the 1990s [44], our participants
believed it is impractical to solicit informed consent for
every disorder on a panel when screening for large num-
bers of disorders. Generic consent, which would broadly
describe the nature of the test, instead of focusing on
the medical aspects of individual conditions, has been
proposed as a viable alternative for ECS with consider-
able advantages [15]. However, our participants sug-
gested that in order to enhance reproductive autonomy,
prospective parents should be able to choose which dis-
orders they would like to be screened for, rather than be-
ing locked into an all-or-nothing offer for a panel of
diverse disorders [45]. To address this, some commenta-
tors have proposed clustering disorders into different
categories or tiers based on characteristics such as severity
or age of onset, and allowing patients to make choices be-
tween these categories [38, 46]. A tiered approach to con-
sent was supported by some of our participants, who
viewed it as a middle ground solution between disease-
specific and generic consents. However, it is unclear
whether clustering disorders into multiple categories is
helpful for prospective parents to make informed discrim-
inatory choices among the categories. The utility of a
tiered consent is currently being evaluated and, if shown
to be beneficial, may gain further support within the pro-
fessional genetic community [47].
Our participants believed that face-to-face post-test
genetic counseling discussing the clinical characteristics
of the disorder and their available reproductive options
should be provided to all carrier couples identified by
ECS. The medical information provided to carrier cou-
ples should be comprehensive and up-to-date, including
an overview of the latest and emerging therapeutic inter-
ventions [48]. To this end, our participants felt carrier
couples would benefit from an additional consultation
with a medical professional with clinical expertise in
the disorder and also the opportunity to interact with
affected individuals, or their family members. Some pa-
tient organizations have also recommended the availability
Janssens et al. BMC Medical Ethics  (2017) 18:46 Page 8 of 10of patients or their family members for a consultation, to
help at-risk future parents to gauge the burden of the dis-
ease and make informed reproductive decisions [49]. Im-
portantly, while this may be possible in relatively common
disorders, such as CF, couples at risk of having a child
with a rare disorder may not have the same opportunities.
Therefore, in many cases carrier couples will be reliant on
genetic counselors to help them contemplate the potential
impact of having an affected child. Therefore it is crucial
that genetic counselors are prepared to provide informa-
tion and support about all the disorders on the ECS panel.
The findings of our study are in some respects com-
parable to those presented by Cho et al. and McGowan
et al., based on focus group discussions involving geneti-
cists from the US. In both studies, geneticists empha-
sized the importance of pre- and post-test information
and counseling aimed at facilitating informed decision
making among prospective parents [12, 13]. However,
we observed strong disagreement among our partici-
pants regarding the acceptability of screening individ-
uals, which was not described is the US-based study. In
addition, according to some participants in our study, in
order to ensure that only motivated prospective parents
take the test, it may be appropriate to add certain bar-
riers to test access, such as requiring a repeat-visit. This
differs from the findings of McGowan et al., where partici-
pants believed that most healthcare providers will be com-
pelled to routinely offer ECS in order to avoid liabilities
should an affected child be born and did not discuss strat-
egies aimed at maximizing informed decision-making
[13]. The possibility of holding healthcare providers ac-
countable due to their failure to offer ECS was conspicu-
ously absent in our interviews, which may be explained by
differences in legal frameworks governing the practice of
reproductive medicine.
Limitations
Our study purposively sampled geneticists with expertise
in carrier screening for recessive disorders. Therefore,
while the study provides valuable insights into the key
ethical and practical challenges associated with the im-
plementation of ECS, their opinions are not necessarily
generalizable to those of geneticists in Europe more
broadly. Future studies including participants without
expert knowledge in carrier screening would be a valu-
able contribution to the literature. In the context of
population-wide screening the task to initiate discussions
about ECS with prospective parents is likely to fall on
healthcare providers, such as obstetrician-gynecologists
and general practitioners, rather than geneticists. However,
some of these non-geneticist healthcare professionals may
not be well-prepared to provide adequate guidance and
genetic counseling to their patients regarding ECS. There-
fore, exploring attitudes of non-genetics professionalsshould also be undertaken in order to gain a more compre-
hensive understanding of the practical challenges they fore-
see with the implementation of ECS in the public health
setting. Finally, it should be noted that even though most
ECS tests are currently offered through commercial genetic
testing companies, the views of commercial providers re-
garding ECS remain largely unexplored. Thus, it is import-
ant that future empirical studies focus on the views of
commercial providers, such as direct-to-consumer genetic
testing companies.
Conclusions
We identified that our participants placed high import-
ance on ECS being offered preconceptionally and in the
setting of couple-based screening. This highlights a need
for both adequate education and counseling services,
but also underscores the importance of making efforts
to facilitate access to ECS before pregnancy. To ensure
that prospective parents understand the complex infor-
mation pertaining to ECS, pre-test information can be
provided through patient-centered education aids, par-
ticularly videos and computer-based interactive tools. In
the post-test setting, in-person genetic counseling is in-
dicated in couples found to be at risk of conceiving an
affected child. However, practical challenges in optimiz-
ing pre-test education and post-test counseling should
not be underestimated and they should be carefully ad-
dressed before implementing ECS in the clinical setting.
Our study has also provided valuable insights into the
important differences between individual and couple-
based strategies in carrier screening. While the superior-
ity of either of the approaches cannot be determined
without taking into consideration the local context, it is
important that decision-makers acknowledge substantial
differences between the two approaches and give due
consideration to identifying the optimal screening and
reporting strategies. Future studies need to focus on the
preferences between the two approaches among different
stakeholders, such as healthcare providers offering ECS
and couples undergoing carrier screening.
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